Vor Biopharma
Financing Rounds
- Series B
- Public
Round Led or Co-led By SymBiosis
Round Led or Co-led By SymBiosis
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.
Modality
- Cell Therapy
Indication
- Oncology
Development Status
- Phase 1